Drugs / JW0104
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06754943 | Jan → Mar 2025 | — | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT06378684 | Sep → Dec 2023 | — | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06643130 | Dec 2024 → Apr 2026 overdue | hyperlipidemia, hypertensive disorder | JW Pharmaceutical | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JW0104 | “Co-administration of 1 tablet of JW0104 and 1 tablet of C2402” NCT06754943 ↗ |
| Route | Oral | “Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration” NCT06378684 ↗ |